Nuclear receptor subfamily 4 group A member 2 (NR4A2) (NURR1)

Nuclear receptor subfamily 4 group A member 2 (NR4A2), commonly known as NURR1, is an orphan nuclear receptor that functions as a ligand-independent transcription factor (UniProt P43354). It plays a critical role in the development, survival, and maintenance of midbrain dopaminergic neurons by regulating the expression of essential genes like tyrosine hydroxylase and the dopamine transporter (PubMed: 25938226). Due to its vital role in dopaminergic health, NURR1 is a primary therapeutic target for Parkinson's disease, where its expression is often significantly reduced in the substantia nigra (PubMed: 12524514). Beyond neurodegeneration, NURR1 is involved in modulating inflammatory responses and has been implicated in autoimmune diseases like rheumatoid arthritis and various cancers (PubMed: 29653123). Current drug discovery efforts focus on identifying small-molecule agonists, such as the antimalarial drugs amodiaquine and chloroquine, which have shown potential in enhancing NURR1 activity and protecting dopaminergic neurons in preclinical models (PubMed: 26124146). As an orphan receptor, its therapeutic modulation remains a complex challenge involving the balance of neuroprotective benefits against potential systemic side effects.

Other names

NR4A2Nuclear receptor-related protein 1NOTTINURHZF-3Immediate-early response protein NOTTranscription factor NOT

Agonism of the nuclear receptor to enhance the transcription of genes involved in dopamine synthesis and transport, such as tyrosine hydroxylase and the dopamine transporter, thereby restoring dopaminergic function and providing neuroprotection.